Corticotropin-releasing factors (CRF) secreted by the rat median eminence in vitro in the presence or absence of ascorbic acid: quantitative role of vasopressin and catecholamines
- PMID: 6266808
- DOI: 10.1210/endo-109-3-813
Corticotropin-releasing factors (CRF) secreted by the rat median eminence in vitro in the presence or absence of ascorbic acid: quantitative role of vasopressin and catecholamines
Abstract
Microdissected rat median eminences (wet weight, 110 micrograms) were electrically stimulated in vitro in the presence of bacitracin and bovine serum albumin. Incubation media collected at 20-min intervals, were assayed for corticotropin-releasing factor (CRF) with dispersed pituitary cells and for arginine vasopressin (AVP) by a specific RIA. CRF activity of the media or of synthetic AVP was plotted as function of AVP content. Dose (AVP)-response (CRF) curves for media were not significantly different from those of synthetic AVP. Extracts of incubated median eminences had 3 times more CRF activity then the AVP contained within these extracts, showing that CRF distinct from AVP ws contained within the median eminences but had not been released into or had been degraded within the media. In the presence of 1 mM ascorbic acid, AVP release was not significantly different from AVP release in the absence of ascorbic acid, but accounted for only 49-67% of released CRF activity, suggesting that a CRF distinct from AVP had been released into or protected within the medium. At an AVP level similar to that found in hypophysial portal plasma, the total CRF activity of median eminence media were not significantly different in the presence or absence of 0.13 microM haloperidol or 1.3 microM propranolol in ascorbic acid-rich media, but were 12-17% (P less than 0.05) lower in the presence of 0.35 microM phentolamine. The results indicate that CRFs, distinct from AVP, released from the median eminence in vitro can be detected only when ascorbic acid is present in the medium, and furthermore, that AVP and some alpha-adrenergic agonist account for at least 61-84% of released CRF activity.
Similar articles
-
Marked changes of arginine vasopressin, oxytocin, and corticotropin-releasing hormone in hypophysial portal plasma after pituitary stalk damage in the rat.Endocrinology. 1995 May;136(5):1864-8. doi: 10.1210/endo.136.5.7720631. Endocrinology. 1995. PMID: 7720631
-
Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: studies on the adrenocorticotropin response to ether stress and exogenous CRF.Endocrinology. 1984 Jan;114(1):57-62. doi: 10.1210/endo-114-1-57. Endocrinology. 1984. PMID: 6317350
-
Role of protein kinase-C in the adrenocorticotropin secretory response to arginine vasopressin (AVP) and the synergistic response to AVP and corticotropin-releasing factor by perifused rat anterior pituitary cells.Endocrinology. 1990 Jul;127(1):350-7. doi: 10.1210/endo-127-1-350. Endocrinology. 1990. PMID: 2163316
-
[Role of the neurohypophysis in psychological stress].Encephale. 2001 May-Jun;27(3):245-59. Encephale. 2001. PMID: 11488255 Review. French.
-
[Corticoliberin--structure, occurrence, properties and clinical use].Endokrynol Pol. 1985;36(3):169-85. Endokrynol Pol. 1985. PMID: 3000753 Review. Polish. No abstract available.
Cited by
-
Interference of clonidine and alpha-methyl-p-tyrosine with stress and central histaminergic stimulation of the corticosterone response in rats.Agents Actions. 1984 Apr;14(3-4):550-3. doi: 10.1007/BF01973869. Agents Actions. 1984. PMID: 6145339
-
Synthetic corticoliberin needs arginine vasopressin for full corticotropin releasing activity.Experientia. 1982 Sep 15;38(9):1078-9. doi: 10.1007/BF01955377. Experientia. 1982. PMID: 6290259 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous